UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):July 1, 2016
AMARANTUS BIOSCIENCE HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
| Nevada | | 000-55016 | | 26-0690857 |
(State or other jurisdiction of
incorporation or organization) | | (Commission File Number) | | IRS Employer Identification No.) |
655 Montgomery Street, Suite 900 San Francisco, CA | | 94111 |
| (Address of Principal Executive Offices) | | (Zip Code) |
(408) 737-2734
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Effective July 1, 2016, Robert Farrell resigned as Chief Financial Officer of Amarantus Bioscience Holdings, Inc. (the “Company”) and all positions held with the Company’s subsidiaries. In connection with Mr. Farrell’s resignation, the Company entered into a Release Agreement with Mr. Farrell pursuant to which Mr. Farrell released the Company from all action, claims and demands arising out of his employment with the Company, any agreement concerning his employment or the termination of his employment with the Company.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| | AMARANTUS BIOSCIENCE HOLDINGS, INC. |
| | | |
| Date: July 8, 2016 | By: | /s/ Gerald E. Commissiong |
| | Name: | Gerald E. Commissiong |
| | Title: | Chief Executive Officer |
3
